Several MD Anderson-led studies at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting focus on using immunotherapy to provide new treatment options for rare, aggressive cancers, including anaplastic thyroid cancer (ATC), glioblastoma, leptomeningeal disease (LMD) and soft-tissue sarcomas. For most of these rare diseases, survival is poor and few – if any – effective treatment options are currently available.
As...
An MD Anderson Phase I clinical trial demonstrated that a combination therapy using WNT974, a drug that targets the WNT pathway in cancer,...
President Donald Trump today announced his intent to appoint Hussein Tawbi, M.D., Ph.D., associate professor and deputy chairman of Melanoma...
Combining two types of immune checkpoint inhibitor fires up responses in T cells that are separate from those initiated by the two drugs individually, a research team led by Nobel Laureate Jim Allison, Ph.D., reports in the Proceedings of the National Academy of Sciences.
Administering two immunotherapy antibodies that unleash an immune attack on cancer by separately blocking the CTLA-4 and PD-1 checkpoints on T cells doesn’t have...
An international consortium, led in part by clinicians and researchers from The University of Texas MD Anderson Cancer Center, has published...
Combining two types of drugs that, separately, have extended the lives of people with metastatic melanoma has yielded higher response rates...
Researchers at The University of Texas MD Anderson Cancer Center have shown how pretreatment clonal complexity in pancreatic tumor cells leads...
In October 2018, the Nobel Prize in Physiology or Medicine was awarded to Jim Allison, Ph.D., chair of Immunology, for his discoveries on...
Each May, Skin Cancer Awareness Month serves as a reminder of how individuals can work to lower their risk of skin cancer – the most common...
Melanoma cells are able to evade cancer immunotherapy by using a specific protein to hide from immune system T cells out to seek and destroy...